GABA-polypeptide composite nerve-soothing and wrinkle-removing composition, application thereof and nerve-soothing and wrinkle-removing skin care product

Abstract

The invention relates to a GABA (gamma-aminobutyric acid)-polypeptide composite nerve soothing and wrinkle removing composition and application thereof as well as a nerve soothing and wrinkle removing skin care product. The composition is prepared from gamma-aminobutyric acid, tephrosia purpurea extract and recombinant XVII type collagen in a mass ratio of (0.1-2): (0.1-1.5): (0.1-1.5). Compared with the prior art, a single-dimensional anti-aging mode is broken through, a skin conditioning system with gamma-aminobutyric acid, tephrosia purpurea Seed Extract and recombinant XVII type collagen as main components is constructed, and the components are cooperatively used to form a three-level skin state improvement path of nerve regulation, barrier repair and basement membrane regeneration.

Description

Technical Field

[0001] This invention belongs to the field of daily chemical product technology, and relates to a GABA-peptide complex nerve-soothing and wrinkle-reducing composition and its application, as well as nerve-soothing and wrinkle-reducing skin care products. Background Technology

[0002] Emotional skin aging refers to skin aging triggered by negative emotions. It is a type of "endogenous aging" caused by a disorder of the "nervous system-endocrine system-immune network." Its main manifestations include decreased skin barrier function, deepening wrinkles (dynamic wrinkles transforming into static wrinkles), decreased skin elasticity, dull and sagging skin, and often accompanied by sensitivity and redness. Unlike natural skin aging, its core characteristic is that emotional signals cause physiological disorders in the endocrine system, which in turn affect skin condition, leading to irreversible damage to skin structure over time.

[0003] As we age or experience increased stress, the levels of certain neurotransmitters and hormones secreted by the endocrine system decline significantly. When the body lacks these components, negative emotions such as depression, anxiety, unease, fatigue, and other negative feelings arise, which in turn affect skin condition and lead to skin aging. Furthermore, external environmental factors can also trigger mood changes, causing skin aging problems to occur at increasingly younger ages. To improve skin condition and alleviate anxiety about skin aging, more and more consumers are focusing on skincare products that improve skin condition, driving the continued growth of the anti-aging skincare market.

[0004] In recent years, the fields of dermatology and neuroscience have interacted and combined, and research has continued to deepen, revealing the neural pathways of skin aging. The related molecular mechanisms and processes are becoming increasingly clear, providing new directions and care approaches for combating skin aging. To date, anti-aging products centered on the regulation of neural signals have made significant breakthroughs, and related products are being put into use. Although such methods have achieved good results, they still face two major challenges: (1) Relatively simple active ingredients: Some products use only one or a few active ingredients, which makes the scope of action of this type of skin care product narrow and the improvement effect in many aspects limited. (2) Insufficient transdermal efficiency and utilization: Some active ingredients have large molecular weights and are not easy to penetrate the stratum corneum of the skin, resulting in low penetration efficiency and insufficient cell absorption and utilization.

[0005] Currently, an increasing number of skincare products are attempting to regulate skin condition by improving mood. However, most existing solutions utilize single or a few active ingredients, such as the application of blue chamomile hydrosol in skincare as described in patent CN117243869A. This limits the scope of action of this type of skincare product, failing to intervene in and regulate skin condition from multiple perspectives and pathways, resulting in relatively limited regulatory effects. Furthermore, some soothing skincare products lack comprehensive and lasting improvement effects; once discontinued, skin condition can easily regress.

[0006] For example, the cell-active peptide composition for promoting the regeneration of multi-type collagen structural proteins disclosed in Chinese patent CN119606786B contains ingredients such as tripeptide 10 citrulline, hexapeptide 9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide 3, acetyl tetrapeptide 11, palmitoyl dipeptide 7, and palmitoyl pentapeptide 4. It can promote the synergistic expression of skin type I, III, IV, VII, and XVII collagen, fibronectin, elastin, and glycosaminoglycans. However, its composition system is complex, with dispersed targets, and lacks intervention on the key pathway of "emotional stress-neural excitation-skin aging." It fails to construct a clear multi-level synergistic network, and the mechanism of action of this composition is mainly focused on stimulating endogenous collagen production, which is a single-dimensional structural supplement. It does not involve the immediate relief of skin nerve sensitivity, nor does it regulate the neuroendocrine disorders caused by emotional stress. Therefore, it cannot block the "emotion-wrinkle" link at its source. Furthermore, its claimed effects are mainly focused on improving collagen expression and long-term wrinkle improvement, lacking verification and data support for multi-dimensional effects such as skin barrier function repair, immediate reduction of stinging sensation, and continuous moisturizing.

[0007] In general, most existing mood-soothing skincare products rely on the physical perception of the sensory system, using the aroma and other effects of active ingredients to induce a sense of relaxation in consumers. However, these products fail to consider the multifaceted molecular mechanisms of emotional skin aging and lack regulation of neural pathways, resulting in limited effectiveness in improving skin conditions caused by the nervous system. Summary of the Invention

[0008] The purpose of this invention is to provide a GABA-peptide complex neuro-soothing and wrinkle-reducing composition and its application, as well as neuro-soothing and wrinkle-reducing skin care products. By constructing a three-level skin condition improvement pathway of neuro-regulation-barrier repair-basement membrane regeneration, it achieves a synergistic enhancement effect in terms of immediate soothing, reducing skin sensitivity / stirring, improving skin hydration, enhancing skin elasticity and / or wrinkle improvement.

[0009] The objective of this invention can be achieved through the following technical solutions: In a first aspect, the present invention provides a GABA-peptide complex nerve-soothing and wrinkle-reducing composition, comprising γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen, wherein the mass ratio of the three is (0.1-2):(0.1-1.5):(0.1-1.5).

[0010] Furthermore, the mass ratio of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen is (0.5-2):(0.5-1.5):(0.5-1.5).

[0011] Furthermore, the mass ratio of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen is (0.5~1.5):(0.5~1.5):(0.5~1.5).

[0012] In a second aspect, the present invention provides the application of the GABA-peptide complex nerve-soothing and wrinkle-reducing composition as described in the first aspect in the preparation of soothing and wrinkle-reducing skin care products.

[0013] Furthermore, the soothing and wrinkle-reducing skincare product is a face cream, toner, serum, or lotion.

[0014] In a third aspect, the present invention provides a soothing and wrinkle-reducing skin care product, comprising a base excipient and an active ingredient, wherein the active ingredient is the GABA-peptide complex nerve-soothing and wrinkle-reducing composition as described in the first aspect above, and the amount of the active ingredient added is 0.5~10wt%.

[0015] Furthermore, the skincare product is a serum, and the base excipients include phase A, phase B, phase C, and phase D excipients, wherein, based on the total weight of the skincare product, The A-phase excipients include 5-15 wt% humectant, 0.1-0.2 wt% thickening regulator, and 0.02-0.1 wt% stabilizer; The B-phase excipients include 0.5-1.5 wt% sealing agent and 0.1-0.5 wt% antioxidant; The C-phase excipients include a pH adjuster of 0.1-1 wt%; The D-phase excipients include 0.5-2 wt% preservatives and 0.1-0.3 wt% fragrances.

[0016] Furthermore, the moisturizer is one or a combination of several of the following: glycerin, 1,3-butanediol, panthenol, and hyaluronic acid; The thickening regulator is carbomer; The stabilizer is EDTA-disodium; The sealing agent is squalane; The antioxidant is tocopherol acetate; The pH adjuster is triethanolamine; The preservative is one or a combination of two of phenoxyethanol or ethylhexylglycerin; The fragrance is a flavoring.

[0017] More preferably, based on the total weight of the skincare product, the A-phase excipients include 4.0 wt% glycerin, 3.0 wt% 1,3-butanediol, 3.0 wt% panthenol, 0.2 wt% hyaluronic acid, 0.15 wt% carbomer, and 0.05 wt% disodium EDTA. The B-phase excipients include 1.0 wt% squalane and 0.2 wt% tocopheryl acetate. The C-phase excipient includes 0.5 wt% triethanolamine; The D-phase excipients include 0.8 wt% phenoxyethanol, 0.2 wt% ethylhexylglycerin, and 0.2 wt% fragrance.

[0018] Furthermore, based on the total weight of the skincare product, the A phase excipients include deionized water supplemented to a total of 100 wt%.

[0019] Compared with the prior art, the present invention has the following advantages: (1) It uses γ-aminobutyric acid, edamame extract and recombinant type XVII collagen as the main ingredients to improve skin condition from multiple pathways and angles, forming a three-level regulatory network of nerve regulation-barrier repair-basement membrane regeneration, which takes into account both immediate soothing and long-term repair effects.

[0020] (2) Gamma-aminobutyric acid (GABA) is the main component that provides immediate relief. It inhibits the over-excitation of nerve endings in the skin and soothes the skin's stress response. On the one hand, it can reduce the transmission of excitatory signals, relieve local muscle tension from the source, and block the "emotional stress-muscle contraction-wrinkle deepening" chain reaction. On the other hand, it can inhibit the secretion of pro-inflammatory factors in nerve endings to a certain extent, thus having a certain soothing and anti-inflammatory effect. Edamame extract and recombinant type XVII collagen are the main components that provide long-lasting repair. Edamame extract exerts its soothing effect by regulating the stress nerve signals of skin cells. Recombinant type XVII collagen is a key structural protein in the basement membrane region. It can participate in the connection between the epidermis and dermis, anchoring the basal cells of the epidermis to the dermis, thus ensuring the stable and continuous arrangement of the basal cells and forming a "physical barrier," thereby improving skin laxity and maintaining skin elasticity.

[0021] (3) The synergistic use of γ-aminobutyric acid, edamame extract and recombinant type XVII collagen breaks through the limitations of existing technologies in improving skin condition and has significant advantages. Attached Figure Description

[0022] Figure 1 The changes in the crow's feet wrinkles of the subjects at different times. Detailed Implementation

[0023] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments. These embodiments are based on the technical solution of the present invention and provide detailed implementation methods and specific operating procedures. However, the scope of protection of the present invention is not limited to the following embodiments.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

[0025] As used herein, the terms "and / or," "or / and," and "and / or" encompass any one of two or more of the related listed items, as well as any and all combinations of the related listed items. These arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected using at least two conjunctions selected from "and / or," "or / and," and "and / or," it should be understood that, in this application, the technical solution undoubtedly includes solutions connected by "logical AND," and also undoubtedly includes solutions connected by "logical OR."

[0026] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.

[0027] In this application, numerical ranges are referred to as continuous unless otherwise specified, and include the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0028] This document only specifically discloses some numerical ranges. However, any lower limit can be combined with any upper limit to form an unspecified range; and any lower limit can be combined with other lower limits to form an unspecified range, just as any upper limit can be combined with any other upper limit to form an unspecified range. Furthermore, each individually disclosed point or single value can itself serve as a lower or upper limit and be combined with any other point or single value or with other lower or upper limits to form an unspecified range.

[0029] Unless otherwise specified, the temperature parameters in this application may be either constant temperature processing or processing within a certain temperature range. The constant temperature processing allows temperature fluctuations within the precision range controlled by the instrument, such as ±5°C, ±4°C, ±3°C, ±2°C, or ±1°C.

[0030] In this document, the term "suitable" as used in phrases such as "suitable combination," "suitable method," and "any suitable method" refers to the ability to implement the technical solution of this application, solve the technical problem of this application, and achieve the expected technical effect of this application.

[0031] In this application, terms such as "further," "even further," and "particularly" are used to describe purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0032] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it means that it is selected from either "with" or "without." If there are multiple "optional" entries in a technical solution, unless otherwise specified, and there are no contradictions or mutual constraints, each "optional" entry shall be independent.

[0033] In the description of the application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0034] Unless otherwise specified, all preparations and tests described herein took place at 25°C.

[0035] The terms “comprising,” “including,” “containing,” “having,” “comprising,” or other variations thereof are intended to cover non-closed inclusion, and no distinction is made between these terms. The term “comprising” means that other steps and ingredients may be added without affecting the final result. The compositions and methods / processes of the present invention comprise, consist of, and substantially consist of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, steps, or limitations described herein. No distinction is made between the terms “efficacy,” “performance,” “effect,” and “potency” herein.

[0036] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions. Unless otherwise specified, all technical features and optional technical features of this application can be combined to form new technical solutions.

[0037] Unless otherwise specified, all steps of this application may be performed sequentially or randomly, but sequentially is preferred.

[0038] To achieve synergistic enhancement in terms of immediate soothing, reducing skin sensitivity / stirring, improving skin hydration, enhancing skin elasticity, and / or improving wrinkles, this invention provides a GABA-peptide complex nerve-soothing and wrinkle-reducing composition, comprising γ-aminobutyric acid (GABA), edamame extract, and recombinant type XVII collagen, in a mass ratio of (0.1-2):(0.1-1.5):(0.1-1.5). Preferably, the mass ratio of GABA, edamame extract, and recombinant type XVII collagen is (0.5-2):(0.5-1.5):(0.5-1.5), more preferably (0.5-1.5):(0.5-1.5):(0.5-1.5).

[0039] The nerve-soothing and wrinkle-reducing composition provided by this invention breaks through the single-dimensional anti-aging model and constructs a skin-regulating system with γ-aminobutyric acid, Tephrosia purpurea seed extract, and recombinant type XVII collagen as the main components. Gamma-aminobutyric acid (GABA) is a naturally occurring inhibitory neurotransmitter in the human body. It inhibits excessive excitation of nerve endings in the skin and soothes skin stress responses. When a person experiences emotional stress (such as anxiety or tension), it causes nerve endings in the skin to release excessive amounts of excitatory neurotransmitters (such as acetylcholine), triggering sustained contraction of facial muscles (such as frowning). Over time, this can transform these dynamic wrinkles into static wrinkles. GABA can competitively bind to neurotransmitter receptors, inhibiting sodium ion influx, reducing nerve impulse conduction rate, and decreasing the transmission of excitatory signals. This relieves local muscle tension at its source and blocks the "emotional stress-muscle contraction-wrinkle deepening" chain reaction. In addition, GABA can also inhibit the secretion of pro-inflammatory factors in nerve endings to some extent, exhibiting certain soothing and anti-inflammatory effects.

[0040] Tephrosia purpurea Seed Extract, derived from the seeds of the legume Tephrosia purpurea, is a water-soluble extract rich in oligosaccharides (such as isomaltotriose stachyose and ciceritol). It exerts a soothing effect by regulating stress-related nerve signals in skin cells. In vitro studies have shown that it significantly reduces cortisol secretion by skin cells and stimulates the production of β-endorphins. β-endorphins are endogenous calming peptides; their release produces feelings of pleasure and relieves tension. Simultaneously, reducing cortisol helps alleviate skin stress responses. Tephrosia purpurea extract can "promote the release of relaxing neuropeptides (endorphins), reduce skin redness, break down cortisol production in skin cells, and activate the release of natural calming neuropeptides that affect mood." In summary, this ingredient possesses anti-stress, anti-fatigue, and calming properties, relieving facial tension and sensitivity at the neuroendocrine level.

[0041] Recombinant type XVII collagen is a key structural protein in the basement membrane region. Its main function is to repair the skin's physical barrier and provide "attachment anchors" for keratinocytes, reducing the stimulation of the nervous system by external environmental factors and further consolidating the repair effect. Type XVII collagen is a core component connecting the epidermis and dermis. By anchoring the basal cells of the epidermis to the dermis, it ensures the stable and continuous arrangement of the basal cells, forming a "physical barrier." In addition, due to the connecting effect of type XVII collagen on the epidermis and dermis, it can improve skin laxity to a certain extent and maintain skin elasticity.

[0042] Thus, through the combination of these three components, this invention constructs a synergistic system of nerve relaxation, barrier repair, and basement membrane regeneration. On one hand, exogenous GABA, as an inhibitory neurotransmitter analog, can rapidly intervene in the electrophysiological conduction of local nerve endings, reducing local excitability of facial muscles and weakening muscle contraction, producing an immediate facial relaxation effect, thereby reducing the immediate traction of dynamic wrinkles on the skin. On the other hand, *Echinops latifolius* extract, by inhibiting local cortisol production and promoting the release of endogenous sedative peptides (such as endorphins), inhibits stress responses, weakens inflammatory amplification pathways, and reduces nerve sensitivity at the neuroendocrine level, achieving short- to medium-term homeostasis reconstruction and soothing protection. Furthermore, recombinant type XVII collagen can specifically promote the repair and anchoring of the epidermal-dermal interface (DEJ) structure, enhance the attachment and arrangement of keratinocytes, restore barrier function, and provide mechanical support to achieve long-term wrinkle inhibition and skin tightening. These three components compensate for and promote each other. The compound system described in this invention exhibits a synergistic effect in providing immediate relief, reducing skin sensitivity / irritation, improving skin hydration, and enhancing skin elasticity and wrinkle reduction.

[0043] The GABA-peptide complex nerve-soothing and wrinkle-reducing composition mentioned in this invention has significant advantages in terms of immediate soothing and long-lasting repair effects, and can be used as an active ingredient in skincare products. Skincare products include, but are not limited to, toners, serums, lotions, and creams. In preparation, in addition to the above composition, the skincare products also include the base components necessary for the production of various skincare products. These base components can be selected from conventional base components used in existing products, and the skincare products can be prepared using conventional methods according to existing technologies.

[0044] The present invention will be further described below with reference to specific embodiments.

[0045] I. In vitro cell experiments To verify the efficacy of the combination of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen, this embodiment first prepared the effective components according to Table 1 below and then directly tested them.

[0046] Table 1 The preparation process of the above-mentioned active ingredients is as follows: γ-aminobutyric acid, edamame extract, recombinant type XVII collagen and all components of the base matrix are directly mixed evenly to obtain the active ingredients.

[0047] 1. Capsaicin receptor (TRPV1) activation and inhibition experiment Cultured human keratinocytes (HaCaT) were seeded into 96-well black plates and loaded with a calcium ion fluorescent probe (Fluo-4AM). Each treatment solution listed in Table 1 was added and incubated for 1 hour, followed by capsaicin stimulation. Fluorescence intensity changes were immediately monitored in real-time using a fluorescence microplate reader, and the fluorescence peak inhibition rate was calculated.

[0048] Table 2 TRPV1 activation inhibition rate (%) Skin sensitivity and tingling are closely related to the overactivation of the capsaicin receptor TRPV1. The immediate soothing effect of the composition can be visually evaluated by detecting changes in calcium ion influx (fluorescence intensity) in cells under capsaicin stimulation.

[0049] Table 2 shows that experimental groups 1-3, containing all three components, exhibited the highest inhibition rates against capsaicin-induced TRPV1 receptor activation, reaching 65.2%, 72.8%, and 78.3%, respectively, with a concentration-dependent increasing trend. Compared to experimental group 1, control groups 1-3, lacking any active ingredient, showed significantly reduced inhibitory effects, with inhibition rates of only 45.7%, 38.4%, and 50.1%, respectively. Control groups 4-6, containing only a single active ingredient, showed almost no effective transient neurosoothing ability, with inhibition rates all below 16%. These results clearly demonstrate that the synergistic effect of γ-aminobutyric acid (GABA), *Echinops latifolius* extract, and recombinant type XVII collagen most effectively inhibits excessive excitation of skin nerve endings and pain signal transmission, thus validating the excellent immediate soothing and anti-sensitivity potential of the composition at the cellular level. Furthermore, the absence of any single component significantly weakened the immediate neuromodulation effect, proving the indispensability and synergy of the three components in this function.

[0050] II. Skincare Product Performance Testing To directly verify the efficacy of the GABA-peptide complex nerve-soothing and wrinkle-reducing composition of the present invention in skin care products, and to fully demonstrate the synergistic effect of γ-aminobutyric acid, edamame extract and recombinant type XVII collagen, which are indispensable and cannot be replaced by conventionally recognized "alternative ingredients", the composition was directly added to skin care products (taking serum as an example) in a specific ratio for efficacy evaluation. The content of each component is shown in Table 4 below.

[0051] Table 3 Serum Formula Ratio Table 4. Content (wt%) of each active ingredient in the serum The difference between Examples 1-3 is the content of each active ingredient. The difference between Comparative Examples 1-3 and Example 1 is that only one key active ingredient is missing. The difference between Comparative Examples 4-6 and Example 1 is that only two key active ingredients are missing. The difference between Comparative Examples 7-9 and Example 1 is that only a single key active ingredient is replaced. The difference between the blank comparative example and Example 1 is that the blank comparative example 10 lacks all active ingredients.

[0052] According to the formulation ratios in Tables 3 and 4 above, the preparation method of the serum in this embodiment is as follows: (1) Aqueous phase preparation: Deionized water was placed in the reactor, and glycerol, 1,3-butanediol, panthenol, hyaluronic acid, carbomer, disodium EDTA, edamame extract, γ-aminobutyric acid, and recombinant type XVII collagen were weighed according to the formula and slowly added to the reactor. The reactor was heated in a water bath at 30°C and stirred continuously to ensure that all components were fully dissolved.

[0053] (2) Preparation of oil phase: Weigh squalane and tocopheryl acetate into the reactor according to the formula ratio, heat in a water bath at 30°C, stir and mix until a transparent and uniform system is formed.

[0054] (3) Aqueous-oil phase mixing: Slowly pour the prepared oil phase into the aqueous reactor while stirring at a speed of 200-500 rpm for 30 minutes to ensure uniform emulsification of the system (no layering, no oil droplets).

[0055] (4) Add phenoxyethanol, ethylhexylglycerin and fragrance to the mixture, adjust the pH to 5.5~6.0 with triethanolamine, and finally homogenize to obtain the essence.

[0056] The above-prepared serum was subjected to efficacy evaluation tests: 1. Human efficacy evaluation experiment (1) Test sample: The serum prepared from the components of Examples 1-3, Comparative Examples 1-9 and Blank Comparative Example 10 as described in Table 3 (2) Test subjects: 39 healthy individuals aged 25 to 60 years, all of whom had some static wrinkles on their faces and all had sensitive skin. Written informed consent was signed before the test, and then the participants were randomly divided into 13 groups, with each group using the same product.

[0057] (3) Long-term repair testing method: ① Subjects completed facial cleansing at the testing center, sat quietly for 30 minutes in a constant temperature and humidity environment, and then used the C-cube skin wrinkle tester to test the area of ​​wrinkles around the eyes and the stratum corneum moisture content tester to test the skin moisture content.

[0058] ② Subsequently, on the second day of the test, each group member used the corresponding test serum and applied it to the skin for a period of time. On the 14th day of the test, the area of ​​wrinkles around the eyes was measured using the C-cube skin wrinkle tester, and the skin moisture content was measured using the stratum corneum moisture content tester.

[0059] ③ In addition, after using the serum for 28 and 56 days, the area of ​​wrinkles around the eyes was tested again using the C-cube skin wrinkle tester, and the skin moisture content was tested using the stratum corneum moisture content tester.

[0060] (4) Immediate relief test method: ① Cleaning: Clean the sides of the subject's nose with mild water or a non-irritating cleanser, and gently pat dry with a tissue.

[0061] ② Prepare the test solution: Drop about 0.2 ml of 10% lactic acid solution onto the gauze / filter paper that has been placed in the Finn Chamber beforehand, and make it completely wet.

[0062] ③ Apply Finn Chamber containing equal amounts and concentrations (e.g., 0.2 ml, 10%) of lactic acid to symmetrical positions on both sides of the nose.

[0063] ④ Apply for 5 minutes. During this period, at 2.5 minutes and 5.0 minutes, ask for and record the subjective stinging score (0-3 points) on both sides.

[0064] ⑤ At 5 minutes, the Finn Chambers on both sides were removed simultaneously. Within 1 minute of removing the lactic acid, researchers, in a blindfolded state, applied 0.1 mL of serum and saline solution evenly to the corresponding nasal wing.

[0065] ⑥ Ask the subjects about the stinging sensation on both sides of their nose immediately after application, 1 minute later, and 5 minutes later.

[0066] (5) Test instructions ①Test environment: 20~22°C, relative humidity 40~60%.

[0067] ② The C-cube skin wrinkle tester can capture detailed information about a person's face, forming an image of facial wrinkles. Through software analysis of the skin's surface texture, algorithms are used to identify wrinkles and calculate their area. The user must remain relaxed and natural during the test.

[0068] ③The stratum corneum moisture content tester reflects the moisture status of the skin by detecting the conductivity of the outermost layer of the skin.

[0069] ④ Stinging sensation rating scale (4-point scale): 0 points: no stinging sensation; 1 point: mild stinging sensation (perceptible but not uncomfortable); 2 points: moderate stinging sensation (significant discomfort); 3 points: severe stinging sensation (intense stinging pain that is difficult to tolerate); The stinging sensation scores at the three time points are added together to obtain a total stinging sensation score (range 0-9 points). Subjects with a total stinging sensation score ≥ 3 points are considered to have a positive lactic acid stinging test, meaning that their cutaneous sensory nerve sensitivity is high.

[0070] ⑤ Test results can be calculated using the following formula: Change rate = (Analysis value after product use - Analysis value before product use) / Analysis value before product use × 100%. The average change rate for the same group is taken.

[0071] (6) Test results ① Anti-wrinkle and repair effects Based on the above experimental steps, the area of ​​wrinkles around the eyes was measured using the C-cube skin wrinkle tester at different times. The data from each group were statistically calculated, and the following results were obtained.

[0072] Table 5. Changes in the area of ​​crow's feet in different groups of subjects at different time points. As shown in Table 5, the composition provided by this invention exhibited significant anti-wrinkle and repair effects during a 56-day human efficacy evaluation. Firstly, Examples 1-3, with their complete ingredient combinations, demonstrated the best wrinkle-improving ability at all time points. Example 3 had the highest total content of active ingredients and its effect was the most prominent, with a 20.12% reduction in the area of ​​crow's feet wrinkles after 56 days of use. The effects of Examples 2 and 1 decreased sequentially, indicating that the efficacy of the composition is dose-dependent within a certain range. Simultaneously, all example groups showed time dependence, meaning that the longer the use, the more significant the improvement effect. Secondly, the experimental data strongly validated the synergistic effect of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen. Comparative Examples 1-3, lacking any one of the core ingredients, showed a significant decrease in anti-wrinkle effects, with wrinkle improvement rates at 56 days only reaching 75% to 83% of those in Example 1. This indicates that each of the three components contributes a unique and irreplaceable function: γ-aminobutyric acid (GABA) is responsible for immediate relief and inhibition of excessive muscle contraction; edamame extract regulates neuroendocrine stress; and recombinant type XVII collagen provides long-term structural support and repair. Together, they constitute a complete anti-wrinkle pathway of "neuromodulation-barrier repair-basement membrane regeneration." Furthermore, comparative examples 7-9, which used bisabolol, olive leaf extract, and palmitoyl tripeptide-5 as substitutes, showed better effects than the corresponding groups lacking only a single component, but were still significantly less effective than Example 1 with all components. This result further confirms the irreplaceability of the core components selected in this invention, and that conventional soothing or anti-aging ingredients cannot replicate their specific synergistic mechanism. In addition, comparative examples 4-6, which contained only one or two active ingredients, showed weak anti-wrinkle effects, highlighting the limitations of single-pathway intervention and emphasizing the necessity of this invention to achieve synergistic effects through multi-target, multi-level synergy.

[0073] ② Moisturizing and water-locking effect Based on the above experimental steps, the skin moisture content of the subjects was tested using a stratum corneum moisture content tester at different times, and compared with the skin moisture content before the test. The data of each group were statistically calculated, and the following results were obtained: Table 6. Changes in facial skin moisture content of subjects in different groups at different time points. As shown in Table 6, during the 56-day evaluation of moisturizing efficacy, the composition of this invention demonstrated excellent and sustained ability to improve skin hydration. Examples 1-3 showed the most significant increase in skin moisture content, with Example 3, having the highest total content of active ingredients, exhibiting the best effect, achieving a 23.53% increase in skin moisture content after 56 days. Furthermore, the moisturizing effect of each group accumulated and stabilized with prolonged use. Comparative Examples 1-3, lacking any one of the following components—γ-aminobutyric acid (GABA), edamame extract, or recombinant type XVII collagen—showed a significant decrease in moisturizing effect, with the moisture content increase rate after 56 days being only about 75% to 85% of that of Example 1. This indicates the unique division of labor and synergy among the three components in the moisturizing dimension: GABA indirectly benefits barrier stability by soothing neuroinflammatory factors; edamame extract maintains homeostasis by regulating stress; and recombinant type XVII collagen directly enhances the integrity of the epidermal-dermal junction, thereby strengthening the physical water-locking barrier. Together, these three components constitute a highly efficient "neuro-homeostasis-structure" moisturizing network. Comparative Examples 7-9, which used bisabolol, olive leaf extract, or palmitoyl tripeptide-5 as substitutes, showed slightly better moisturizing effects than their respective single-deficiency groups, but were still significantly lower than Example 1, which contained all ingredients. This further confirms the irreplaceable nature of the core ingredients selected in this invention in the synergistic moisturizing pathway, and that conventional ingredients cannot fully replicate its unique multi-layered synergistic moisturizing mechanism. Comparative Examples 4-6, which contained only one or two active ingredients, showed weak moisturizing effects, indicating the limitations of a single mechanism in addressing complex skin hydration issues.

[0074] ③ Immediate soothing effect Based on the above experimental steps, VAS scores were assessed on the subjects at different times. The data from each group were statistically analyzed, and the average value was taken to obtain the following results: Table 7. Stinging sensation scores and total scores of subjects in each group at different time points. According to the results of the lactic acid stinging test, all test groups showed similar and significant stinging sensations during lactic acid stimulation, with scores ranging from 2.3 to 2.8. This validated the effectiveness of the stimulation model and indicated that the initial skin sensitivity of the subjects in each group had a consistent baseline. The key difference in efficacy occurred after the irritant was removed and the test sample was applied. Examples 1-3 demonstrated immediate soothing ability. Their total stinging scores, the sum of scores at three time points after sample application, were as low as 2.4, 1.9, and 1.4, respectively, showing a clear dose-dependent effect. Example 3 showed the best effect, followed by Examples 2 and 1. The scores in this group began to decrease significantly immediately after application and were nearly completely soothed within 5 minutes. This indicates that the composition of the present invention can provide immediate soothing protection by rapidly intervening in nerve signal transduction, neutralizing the stimulation response, and strengthening the skin barrier. In contrast, the comparative group, lacking any core ingredient, had a significantly higher total stinging score of 3.5 to 4.4, approximately 1.5 to 1.8 times that of Example 1. Among them, Comparative Example 1, lacking γ-aminobutyric acid (GABA), scored the highest, highlighting the irreplaceable role of this component in the immediate neuromodulation process. Comparative Example 2 lacked edamame extract, and Comparative Example 3 lacked recombinant type XVII collagen; their performance confirmed the key roles of these two components in regulating neuroendocrine stress and providing immediate physical barrier reinforcement, respectively. All three are indispensable, forming a complete efficacy chain. The comparative example group using conventional active ingredients as substitutes had a total tingling score between 2.9 and 3.8, which, while better than the corresponding simple deficiency group, was still significantly higher than Example 1. This result indicates that ingredients commonly used in the art for soothing or anti-aging, such as bisabolol, olive leaf extract, and palmitoyl tripeptide-5, cannot completely replicate or equivalently replace the unique function of the three core components in this invention in a specific synergistic pathway. The comparative example group containing only a single active ingredient and the control group with no active ingredient showed the weakest effects, with total tingling scores as high as 5.1 to 6.5. This further confirms the limitations of single-pathway intervention and highlights the necessity of this invention to achieve synergistic efficacy through multi-target synergy of neural inhibition, stress regulation, and barrier consolidation. The experimental results demonstrate that the combination of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen described in this invention has a significant and irreplaceable synergistic effect in reducing skin nerve sensitivity and providing immediate relief. This combination achieves immediate soothing efficacy far exceeding that of single ingredients or conventional alternative ingredient combinations through a cascade reaction of neural inhibition, stress regulation, and barrier consolidation.

[0075] To more intuitively demonstrate the experimental results, refer to Figure 1Wherein, D0 represents the condition of the subject's crow's feet before using the sample, D14 represents the condition of the crow's feet 14 days after using the sample, D28 represents the condition of the crow's feet 28 days after using the sample, and D56 represents the condition of the crow's feet 56 days after using the sample. After using the sample, the wrinkle morphology and skin condition showed continuous improvement. Compared with D0, the depth and length of wrinkles had initially decreased by D14; the number of fine lines decreased by D28, and the main wrinkles were further faded; by D56, the skin surface smoothness was significantly improved, the crow's feet area appeared fuller and firmer, and the overall youthful contour was obvious. These results are consistent with the quantitative reduction data of wrinkle area in Table 5, jointly confirming that the composition of the present invention has a significant and lasting anti-wrinkle repair effect.

[0076] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A GABA-peptide complex nerve-soothing and wrinkle-reducing composition, characterized in that, It includes γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen, with a mass ratio of (0.1-2):(0.1-1.5):(0.1-1.5).

2. The GABA-peptide complex nerve-soothing and wrinkle-reducing composition according to claim 1, characterized in that, The mass ratio of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen was (0.5-2):(0.5-1.5):(0.5-1.5).

3. The GABA-peptide complex nerve-soothing and wrinkle-reducing composition according to claim 2, characterized in that, The mass ratio of γ-aminobutyric acid, edamame extract, and recombinant type XVII collagen was (0.5~1.5):(0.5~1.5):(0.5~1.5).

4. The use of the GABA-peptide complex nerve-soothing and wrinkle-reducing composition according to any one of claims 1-3 in the preparation of soothing and wrinkle-reducing skin care products.

5. The application of the GABA-peptide complex nerve-soothing and wrinkle-reducing composition according to claim 4, characterized in that, The soothing and wrinkle-reducing skincare products are face creams, toners, serums, or lotions.

6. A nerve-soothing and wrinkle-reducing skincare product, characterized in that, It includes matrix excipients and active ingredients, wherein the active ingredients are the GABA-peptide complex nerve-soothing and wrinkle-reducing composition as described in any one of claims 1-3, and the amount of the active ingredients added is 0.5~10wt%.

7. The nerve-soothing and wrinkle-reducing skincare product according to claim 6, characterized in that, This skincare product is a serum. The base excipients include phase A, phase B, phase C, and phase D excipients. The total weight of the skincare product is calculated as follows: The A-phase excipients include 5-15 wt% humectant, 0.1-0.2 wt% thickening regulator, and 0.02-0.1 wt% stabilizer; The B-phase excipients include 0.5-1.5 wt% sealing agent and 0.1-0.5 wt% antioxidant; The C-phase excipients include a pH adjuster of 0.1-1 wt%; The D-phase excipients include 0.5-2 wt% preservatives and 0.1-0.3 wt% fragrances.

8. The nerve-soothing and wrinkle-reducing skincare product according to claim 7, characterized in that, The moisturizer is one or a combination of several of the following: glycerin, 1,3-butanediol, panthenol, and hyaluronic acid. The thickening regulator is carbomer; The stabilizer is EDTA-disodium; The sealing agent is squalane; The antioxidant is tocopherol acetate; The pH adjuster is triethanolamine; The preservative is one or a combination of two of phenoxyethanol or ethylhexylglycerin; The fragrance is a flavoring.

9. The nerve-soothing and wrinkle-reducing skincare product according to claim 8, characterized in that, Based on the total weight of the skincare product, the A-phase excipients include 4.0 wt% glycerin, 3.0 wt% 1,3-butanediol, 3.0 wt% panthenol, 0.2 wt% hyaluronic acid, 0.15 wt% carbomer, and 0.05 wt% disodium EDTA. The B-phase excipients include 1.0 wt% squalane and 0.2 wt% tocopheryl acetate. The C-phase excipient includes 0.5 wt% triethanolamine; The D-phase excipients include 0.8 wt% phenoxyethanol, 0.2 wt% ethylhexylglycerin, and 0.2 wt% fragrance.

10. The nerve-soothing and wrinkle-reducing skincare product according to claim 7, characterized in that, Based on the total weight of the skincare product, the A phase excipients include deionized water to a total of 100 wt%.

Images